Development | Peptides | Semaglutide
Semaglutide
The peptide is a semaglutide molecule produced through genetic engineering synthesis using Escherichia coli cells. Semaglutide is a hypoglycemic agent - an analog of glucagon-like peptide-1 (GLP-1) and a GLP-1 receptor agonist, used for treating type 2 diabetes and obesity.

The structure of semaglutide is 94% homologous to GLP-1. Compared to GLP-1, semaglutide contains modifications that extend its half-life in the body: alanine at position 8 is replaced with α-aminoisobutyric acid to prevent degradation by dipeptidyl peptidase-4; a C18 fatty acid is attached at position 26 to enhance albumin binding; and lysine at position 34 is replaced with arginine to prevent incorrect attachment of the C18 diacid fatty acid.
AKey functions:
Blood sugar regulation - Semaglutide stimulates insulin production in response to food intake, helping lower blood glucose levels. It also suppresses glucagon production - a hormone that increases blood sugar levels.

Appetite suppression and weight control - The medication slows gastric emptying, promoting prolonged satiety. It acts on hunger centers in the brain, reducing appetite and food intake.

Advantages:
  • Effective blood sugar reduction
  • Significant weight loss promotion
  • Convenient once-weekly dosing schedule
  • Clinically proven reduction of cardiovascular complications risk
Leave your request, and we will contact you.

Would you like us to develop a custom drug?

Сообщение об успешной отправке!